The estimated Net Worth of Bernd Brust is at least 1.12 百万$ dollars as of 3 January 2011. Bernd Brust owns over 11,750 units of Atyr Pharma Inc stock worth over 67,363$ and over the last 16 years Bernd sold LIFE stock worth over 1,048,451$.
Bernd has made over 17 trades of the Atyr Pharma Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Bernd exercised 11,750 units of LIFE stock worth 332,525$ on 3 January 2011.
The largest trade Bernd's ever made was exercising 31,208 units of Atyr Pharma Inc stock on 3 December 2010 worth over 693,754$. On average, Bernd trades about 9,070 units every 35 days since 2008. As of 3 January 2011 Bernd still owns at least 35,454 units of Atyr Pharma Inc stock.
You can see the complete history of Bernd Brust stock trades at the bottom of the page.
Bernd's mailing address filed with the SEC is 5791 VAN ALLEN WAY, , CARLSBAD, CA, 92008.
Over the last 16 years, insiders at Atyr Pharma Inc have traded over 27,288,922$ worth of Atyr Pharma Inc stock and bought 966,653 units worth 5,761,237$ . The most active insiders traders include James C Blair、Gregory T Lucier、Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of 34,257$. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth 8,950$.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Atyr Pharma Inc executives and other stock owners filed with the SEC include: